Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
Creative Biolabs is committed to providing top-notch anti-TROP2 recombinant antibody products and support to assist you in your research endeavors and ultimately contribute to advancements in cancer treatment. We also offer easy access to ordering information, technical support, and customer reviews to help you make an informed decision about purchasing the Anti-HER3 recombinant antibody.
TROP2, also known as TACSTD2, is a cell surface protein that is overexpressed in numerous types of cancers, including breast, lung, colorectal, and pancreatic cancer. Due to its high expression in cancer cells, TROP2 has become an attractive therapeutic target for cancer treatment. Targeting TROP2 with specific therapies has shown promise in inhibiting cancer cell growth and promoting cell death, making it a crucial target for the development of new cancer treatments. Except for cancer, TROP2 has also been found to be involved in other diseases such as inflammatory conditions and autoimmune diseases.
TACSTD2; tumor-associated calcium signal transducer 2; EGP1; GP50; M1S1; EGP-1; TROP2; GA7331; GA733-1; epithelial glycoprotein-1; cell surface glycoprotein TROP2; cell surface glycoprotein Trop-2; pancreatic carcinoma marker protein GA7331; pancreatic carcinoma marker protein GA733-1; gastrointestinal tumor-associated antigen GA7331; membrane component chromosome 1 surface marker 1; membrane component, chromosome 1, surface marker 1; 40kD glycoprotein, identified by monoclonal antibody GA733.
We offer a portfolio of recombinant antibodies against TROP2, including highly specific monoclonal antibodies targeting TROP2. These antibodies are designed to study the role of TROP2 in cancer biology and may have potential therapeutic applications. Our antibodies have been rigorously validated and optimized for various applications, including immunohistochemistry, immunofluorescence, western blotting, and flow cytometry. With high specificity and sensitivity, these antibodies are essential tools for investigating TROP2 expression and function in cancer cells and tissues.
Table 1. Featured anti-TROP2 recombinant antibody products at Creative Biolabs.
Cat. No. | Product Name | Target Species | Host Species | Applications |
HPAB-628-FY | Human Anti-TACSTD2 Recombinant Antibody (HPAB-628-FY) | Human | Human IgG1 | PP, ELISA, FC, ADCC, Inhib |
VS-0723-WK54 | Human Anti-TACSTD2 Recombinant Antibody | Human | Human IgG1 | ELISA, FC |
HPAB-0736-WJ | Mouse Anti-TACSTD2 Recombinant Antibody (HPAB-0736-WJ) | Human | Mouse IgG | ELISA |
HPAB-0303CQ | Mouse Anti-TACSTD2 Recombinant Antibody | Human | Mouse IgG1 | ELISA, Inhib |
TAB-0089CL | Mouse Anti-TACSTD2 Recombinant Antibody (TAB-0089CL) | Human | Mouse IgG | WB, Inhib, Stim, BI |
Ensuring the quality of antibodies is crucial in biomedical research and diagnostics. A robust antibody quality management system is essential to guarantee the reliability and accuracy of experimental results. From the procurement of raw materials to the manufacturing process and final product testing, we take strict quality control measures to find and resolve any potential issues. This includes regular validation and characterization of antibodies, as well as maintaining detailed documentation of production processes and lot-to-lot consistency.
Fig.1 SDS-PAGE analysis of anti-TROP2 antibody
(Cat# HPAB-628-FY, Creative Biolabs).
Fig.2 SEC-HPLC analysis of anti-TROP2 antibody
(Cat# HPAB-628-FY, Creative Biolabs).
Fig.3 FACS analysis of anti-TROP2 antibody
(Cat# HPAB-0303CQ, Creative Biolabs).
Our serum-free mammalian cell expression platform provides one-stop services from gene synthesis to high-quality anti-TROP2 recombinant antibody production at a milligram-to-gram scale. We have more than 5 years of process optimization experience in expression vectors, cloning systems, and high-yielding mammalian cell lines. Our transient expression system is faster, more affordable, and can easily scale up to multi-gram quantities in a matter of weeks. We also have a stable CHO cell line generation platform as an alternative for large amounts (> 5 g) and a consistent antibody supply.
Featured Anti-TROP2 Recombinant Antibody Production Platforms
Fig.7 Milligram-scale anti-TROP2 recombinant antibody production.
Fig.8 Gram-scale anti-TROP2 recombinant antibody production.
Creative Biolabs is committed to providing researchers with the most comprehensive and cutting-edge high-quality recombinant antibodies in different formats. The antibody format includes but is not limited to full length, Fab, scFv, scFv-Fc, scFv-CH3, sc-Fab, full length with different Fc isotypes, etc. Our recombinant antibody expertise covers a diverse set of different engineering strategies. Our products are supported by superior custom engineering services according to your specific requirements.
Fig.6 Full-length anti-TROP2 recombinant antibody production and modalities.
Table 2. Public drug targeting TROP2.
Research phase | Company | Classification | Indications | Details |
Approved | Gilead |
Protein Based Therapies Monoclonal antibody (mAb) |
Metastatic triple-negative breast cancer | S**an targets TROP-2-expressing cancer cells through a humanized antibody (RS7) before subsequently becoming internalized and releasing the topoisomerase I inhibitor SN-38 to induce DNA damage-mediated apoptosis. |
(Disclaimer: The information in this table is just for knowledge sharing and not for marketing or sales purposes.)
Table 3. Therapeutic approaches targeting TROP2 in clinical development.
Highest Development Stage | Sponsor | Condition | Indication |
Pre-Registered | AstraZeneca | Cancer, breast, metastatic | Treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have progressed on and are not suitable for endocrine therapy and received at least one additional systemic therapy |
Pre-Registered | Sichuan Kelun-Biotech Biopharmaceutical | Triple negative breast cancer | In patients with unresectable locally advanced, recurrent or metastatic triple-negative breast cancer who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting) |
Phase I/II | MD Anderson Cancer Center | Cancer, solid tumor | In patients with platinum-resistant ovarian cancer, mesonephric-like adenocarcinoma and pancreatic cancer |
Phase I/II | Mabwell (Shanghai) Bioscience | Cancer, solid tumor | Treatment of adult patients with locally advanced or metastatic solid tumors |
Phase I/II | Bio-Thera Solutions | Cancer, solid tumor | Treatment of TROP2-expressing advanced/metastatic solid tumors, in combination with BAT-1308 |
Phase I/II | BiOneCure Therapeutics | Cancer, solid tumor | As monotherapy or in combination with pembrolizumab in adult patients with advanced cancer |
Phase I/II | OBI Pharma | Cancer, solid tumor | Treatment of patients with advanced solid tumors |
Phase I/II | Duality Biologics | Cancer, solid tumor | In patients with advanced or metastatic solid tumors |
Phase I/II | Shanghai Escugen Biotechnology | Cancer, solid tumor | Treatment of advanced/metastatic solid tumors |
Phase I/II | Pyramid Biosciences | Cancer, solid tumor | Treatment of adults with advanced solid tumors |
Phase I/II | Innovent Biologics | Cancer, solid tumor | In patients with unresectable, locally advanced or metastatic solid tumors, as monotherapy |
Phase I/II | LigaChem Biosciences | Cancer, solid tumor | As monotherapy or in combination with anti-PD-1 monoclonal antibody for the treatment of advanced solid tumors |
Phase I/II | Minghui Pharmaceutical | Cancer, solid tumor | Treatment of advanced or metastatic solid tumors |
Phase I/II | Jiangsu Hengrui | Cancer, solid tumor | In patients with advanced solid tumor |
Phase I | Bio-Thera Solutions | Cancer, solid tumor | In patients with advanced Trop2-positive epithelial solid tumors |
Phase I | SystImmune | Cancer, solid tumor | Treatment of various subtypes of TROP2-positive advanced/metastatic solid tumors |
Preclinical | SystImmune | Cancer, lung | |
Phase I | Fudan-Zhangjiang | Cancer, solid tumor | Treatment of TROP2-expressing advanced/metastatic solid tumors, including lung, breast, stomach, esophagus, colorectal, uroepithelial, bladder and endometrial cancer subtypes |
Phase I | Shanghai Junshi Biosciences | Cancer, solid tumor | In patients with locally advanced or metastatic solid tumors |
Phase I | Myeloid Therapeutics | Cancer | For the treatment of adult patients with advanced or metastatic epithelial tumors |
Preclinical | Roche | Cancer, pancreas | In combination with Gemcitabine |
(Disclaimer: The information in this table is just for knowledge sharing and not for marketing or sales purposes.)
With a vast inventory of high-quality anti-TROP2 recombinant antibodies, our team of dedicated experts is ready to assist you in finding the perfect product for your project. Whether you need a custom order for a TROP2 target or other specific requirements, we are committed to providing you with exceptional customer service and fast delivery times. Contact us today to learn more about how we can support your TROP2 target research efforts and help you achieve your scientific goals.